Innovations in HPV Vaccination and Roles of Nurses in Cervical Cancer Prevention

  • Yildirim, Julide Gulizar (Department of Community Health Nursing, Faculty of Nursing, Ege University) ;
  • Arabaci, Zeynep (Department of Home Care Ventilatory, Kastamonu University)
  • Published : 2015.01.06


The human papilloma virus (HPV) is the main aetiological agent for cervical cancer, one of the most frequent cancers observed in women throughout the world. There are effective programs for reducing the incidence of cervical cancer with HPV vaccination. The objective of this study was to discuss the applicability of the HPV vaccination and the role of nurses in prevention of cervical cancer. Use of bivalent and quadrivalent vaccines has been initiated against the types of HPV which are the primary cause of cancer. The quadrivalent HPV vaccination has entered into the routine vaccination schedule in many European countries for use in children and adolescents between 9-15 years of age and for women between 16-26 years of age, whereas it has been proposed that the bivalent vaccination should be given to girls between 9-18 years of age. While cervical cancer is among the cancers that can be prevented, it is essential to continue screening tests while introducing vaccination in a systematic manner for protection. On this subject, among the most important roles of nurses is to implement the screening programs by fulfilling the caregiving, training and consultancy roles for the society and especially, for high risk groups and to increase the awareness of the people.


HPV vaccines;uterine cervical cancer;screening;nurse's roles;awareness


  1. Al-Darwish AA, Al-Naim AF, Al-Mulhim KS, et al (2014). Knowledge about cervical cancer early warning signs and symptoms, risk factors and vaccination among students at a medical school in Al-Ahsa, Kingdom of Saudi Arabia. Asian Pac J Cancer Prev, 15, 2529-32.
  2. Alhan E (2009). Human papillomavirus vaccine. J Pediatr Inf, 3, 12-6.
  3. Arabaci Z, Ozsoy S (2012). The pap-smear test experience of women in Turkey: a qualitative study. Asian Pac J Cancer Prev, 13, 5687-90.
  4. Ak M, Canbal M, Turan S, Gurbuz N (2010). Attitude concerning the pap smear test of women who admitted to the family medicine outpatient clinic. Konuralp Medical J, 2, 1-4.
  5. Akyuz A, Guvenc G, Yavan T, Cetinturk A, Kok G (2006). Evaluation of the pap smear test status of women and of the factors affecting this status. Gulhane Med J, 48, 25-9.
  6. Ardahan M, Temel AB (2011). Visual inspection with acetic acid in cervical cancer screening. Cancer Nurs, 34, 158-63.
  7. Bilir N (2007). Cervical cancer control studies and HPV vaccine. Public Health Specialist Association Technical Reports Number: 03/2007.
  8. Binagwaho A, Wagner CM, Gatera M, et al (2012). Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull WHO, 90, 623-8.
  9. Brabin L, Roberts SA, Stretch R, et al (2008). Uptake of first two doses of human papilloma virus vaccine by adolescent school girls in Manchester: Prospective cohort study. BMJ, 336, 1056-8.
  10. Brabin L, Stretch R, Roberts SA, et al (2011). The school nurse, the school and HPV vaccination: a qualitative study of factors affecting HPV vaccine uptake. Vaccine, 29, 3192-6.
  11. Casciotti DM, Smith KC, Andon L, et al (2014). Print news coverage of school-based human papilloma virus vaccine mandates. J Sch Health, 84, 71-81.
  12. Duran TE (2011). Examination with the health belief model of women's attitudes to cervical cancer and early diagnosis in Turkey: a qualitative study. Asian Pac J Cancer Prev, 12, 1179-84.
  13. Fidaner C (2007). Early Detection of Cancer: Early Diagnosis and Screenings. Editor: Tuncer AM, Cancer Control in Turkey, Turkish Ministry of Health, 319-32.
  14. Haesebaert J, Lutringer-Magnin D, Kalecinski J, et al (2012). French women's knowledge of and attitudes towards cervical cancer prevention and the acceptability of HPV vaccination among those with 14-18 year old daughters: a quantitativequalitative study. BMC Public Health, 12, 1034.
  15. International Agency for Research on Cancer (IARC) (2012). Cervical Cancer Incidence and Mortality Worldwide in 2012.
  16. Kaya M (2009). Cervical cancer to Community Health Approach. Editor: Akin A, Huksam Press, Ankara, pp 3-30.
  17. Kothari A (2014). HPV vaccination: effects on cervical screening. Nurs Times, 110, 19-21.
  18. Lander J, Besson MH, Hampshire R, et al (2012). Assessment of either HPV vaccination programs implemented in lowest income countries. BMC Public Health, 12, 370.
  19. LaMontagne DS, Barge S, Le NT, et al (2011). Delivery strategies for HPV vaccination programs that achieved high coverage in low and middle-income countries. Bull WHO, 89, 821B-30B.
  20. Limia A, Pachon I (2011). Coverage of human papillomavirus vaccination during the first year of its introduction in Spain. Euro Surveill, 16, 19873.
  21. Molokwu J, Fernandez NP, Martin C (2014). HPV Awareness and Vaccine Acceptability in Hispanic Women Living Along the US-Mexico Border. J Immigr Minor Health, 16, 540-5.
  22. NHS Cancer Screening Programme: The facts leaflet, Annual review 2012.
  23. Ogilvie G, Anderson M, Marra F, et al (2010). A populationbased evaluation of a publicly funded school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med, 7, 1000270.
  24. Ortashi O, Raheel H, Shalal M (2014). Acceptability of human papilloma virus vaccination among women in the United Arab Emirates. Asian Pac J Cancer Prev, 15, 2007-11.
  25. Paul P, Fabio A (2014). Literature review of HPV vaccine delivery strategies: considerations for school and non-school based immunization program. Vaccine, 32, 320-6.
  26. Saslow D, Castle PE, Cox JT, et al (2007). American Cancer society guideline for human papilloma virus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin, 57, 7-28.
  27. Schiller JT, Castellsague X, Garland SM (2012). A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine, 30, 123-38.
  28. Turkish National standards of cervical cancer screening (TNSCCS) (2007). Ministry of Health. Turkey Public Health Institution.
  29. Uysal A, Birsel A (2009). Knowledge about cervical cancer risk factors and pap testing behavior among Turkish women. Asian Pac J Cancer Prev, 10, 345-50.
  30. Waller J, McCaffery K, Forrest S, et al (2003). Awareness of human papillomavirus among women attending a well woman clinic. Sex Transm Infect, 79, 320-2.
  31. Waller J, McCaffery K, Nazroo J, Wardle J (2005). Making sense of information about HPV in cervical screening: a qualitative study. Br J Cancer, 92, 265-70.
  32. Wang SM, Zhang SK, Pan XF, et al (2014). Human papilloma virus vaccine awareness, acceptability, and decision-making factors among Chinese college students. Asian Pac J Cancer Prev, 15, 3239-45.
  33. Watson M, Shaw D, Molchanoff L, McInnes C (2009). Challenges, lessons learned andresults following the implementation of a human papillomavirus school vaccination program in South Australia. Aust N Z J Public Health, 33,365-70.
  34. World Health Organization (WHO) (2013). HPV Vaccine Communication Special considerations for a unique vaccine. WHO Press, World Health Organization, Geneva, Switzerland.
  35. Wong LP, Wong YL, Low WY, Khoo EM, Shuib R (2009). Knowledge and awareness of cervical cancer and screening. Singapore Medical J, 50, 49-53.
  36. Yilmazel G, Duman NB (2014). Knowledge, attitudes and beliefs about cervical cancer and human papilloma virus vaccination with related factors in Turkish university students. Asian Pac J Cancer Prev, 15, 3699-704.